Progress in the treatment of chronic lymphocytic leukaemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses new agents, with different mechanisms of action and in different stages of clinical development, for the treatment of patients with chronic lymphocytic leukaemia (CLL). These include the immunomodulatory agent, lenalidomide, for untreated CLL; the Bruton’s tyrosine kinase inhibitor, ibrutinib, for previously treated CLL; and the monoclonal anti-CD20 antibody, rituximab, for older patients with previously untreated CLL.

Year of Production:
Running Time:


Comments are closed.